L-carnitine decreases myocardial injury in children undergoing open-heart surgery: A randomized controlled trial

Eur J Pediatr. 2024 Jun;183(6):2783-2789. doi: 10.1007/s00431-024-05534-2. Epub 2024 Apr 3.

Abstract

Myocardial injury in open-heart surgery is related to several factors including ischemia-reperfusion injury, generation of reactive oxygen species, increased production of inflammatory mediators, and enhancement of apoptosis of cardiomyocytes. The aim of this study was to study the effect of L-carnitine on myocardial injury in children undergoing open-heart surgery. This clinical trial was performed on 60 children with congenital heart disease (CHD) who underwent open-heart surgery. They were randomized into two groups: L-carnitine group who received L-carnitine 50 mg\kg\day once daily for 1 month before cardiac surgery and control group who received placebo for 1 month before cardiac surgery. Left ventricular cardiac function was assessed by conventional echocardiography to measure left ventricular ejection fraction (LVEF) and two-dimensional speckle tracking echocardiography (2D-STE) to determine left ventricular global longitudinal strain (2D-LV GLS). Blood samples were obtained pre-operatively at baseline before the administration of L-carnitine or placebo and 12 h post-operatively to measure the level of malondialdehyde (MDA), superoxide dismutase (SOD), fas, caspase-3, creatinine kinase-MB (CK-MB), and troponin I. L-carnitine group had significantly lower post-operative level of oxidative stress marker (MDA), apoptosis markers (fas and caspase-3), and myocardial injury markers (CK-MB and troponin I), but they had significantly higher SOD post-operative level compared to the control group. In addition, post-operative LVEF and 2D-LVGLS were significantly lower in the control group compared to L-carnitine group. Conclusion: L-carnitine can reduce myocardial injury, improve post-operative left ventricular cardiac function, and may provide myocardium protection in children with CHD who underwent open-heart surgery. Trial registration: The clinical trial was registered at www.pactr.org with registration number PACTR202010570607420 at 29/10/2020 before recruiting the patients. What is Known: • Myocardial injury in open-heart surgery is related to several factors including ischemia-reperfusion injury, generation of reactive oxygen species, increased production of inflammatory mediators, and enhancement of apoptosis of cardiomyocytes. • L-carnitine was reported to have myocardial protective effects in rheumatic valvular surgery and coronary artery bypass graft (CABG) in adults; however, there is no evidence on its effectiveness in children undergoing open-heart surgery. What is New: • L-carnitine significantly lowered the post-operative level of oxidative stress marker (MDA), apoptosis markers (fas and caspase-3), and myocardial injury markers (CK-MB and troponin I) in the treatment group. • L-carnitine can reduce myocardial injury, improve post-operative left ventricular cardiac function, and may provide myocardium protection in children with CHD who underwent open-heart surgery.

Keywords: Apoptosis; Children; L-carnitine; Open-heart surgery; Oxidative stress.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Apoptosis / drug effects
  • Biomarkers / blood
  • Cardiac Surgical Procedures* / adverse effects
  • Carnitine* / therapeutic use
  • Child
  • Child, Preschool
  • Double-Blind Method
  • Echocardiography*
  • Female
  • Heart Defects, Congenital* / surgery
  • Humans
  • Infant
  • Male
  • Myocardial Reperfusion Injury / etiology
  • Myocardial Reperfusion Injury / prevention & control
  • Oxidative Stress* / drug effects
  • Postoperative Complications / drug therapy
  • Postoperative Complications / prevention & control
  • Treatment Outcome
  • Ventricular Function, Left / drug effects